Gracell Biotechnologies Inc ADR
(GRCL)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | N/A | -41,187 | N/A | -88,080 | N/A |
| Depreciation Amortization | N/A | 3,535 | N/A | 8,520 | N/A |
| Other Working Capital | N/A | -6,442 | N/A | 2,187 | N/A |
| Other Operating Activity | 0 | 5,230 | 0 | 7,395 | 0 |
| Operating Cash Flow | $N/A | $-38,864 | $N/A | $-69,978 | $N/A |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | -2 | N/A | 8 | N/A |
| PPE Investments | N/A | -979 | N/A | -7,016 | N/A |
| Investing Cash Flow | $N/A | $-981 | $N/A | $-7,008 | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 4,827 | N/A | 15,166 | N/A |
| Common Stock Issued | N/A | 20 | N/A | 49 | N/A |
| Other Financing Activity | 0 | -7,053 | 0 | -10,383 | 0 |
| Financing Cash Flow | $N/A | $-2,206 | $N/A | $4,832 | $N/A |
| Exchange Rate Effect | N/A | 4,786 | N/A | 17,877 | N/A |
| Beginning Cash Position | N/A | 200,605 | N/A | 265,181 | N/A |
| End Cash Position | N/A | 163,340 | N/A | 210,904 | N/A |
| Net Cash Flow | $N/A | $-37,265 | $N/A | $-54,277 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | N/A | -38,864 | N/A | -69,978 | N/A |
| Capital Expenditure | N/A | -1,375 | N/A | -7,016 | N/A |
| Free Cash Flow | 0 | -40,239 | 0 | -76,994 | 0 |